Browsing Life sciences and Bio-engineering by Author "Katata, Lebogang"
Now showing items 1-4 of 4
-
Design and formulation of nano-sized spray dried efavirenz-part I: influence of formulation parameters
Katata, Lebogang; Tshweu, Lesego; Naidoo, Saloshnee; Kalombo, Lonji; Swai, Hulda (Springer Nature Switzerland AG., 2012-10-25)Efavirenz (EFV) is one of the first-line antiretroviral drugs recommended by the World Health Organisation for treating HIV. It is a hydrophobic drug that suffers from low aqueous solubility (4 μg/mL), which leads to a ... -
Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.
Tshweu, Lesego; Katata, Lebogang; Kalombo, Lonji; Chiappetta, Diego; Hocht, Christian; Sosnik, Alejandro; Swai, Hulda (NANOMEDICINE, 2014-10-17)Aim: To encapsulate efavirenz (EFV) within poly(epsilon-caprolactone) (PCL) nanoparticles (NPs) and compare the oral pharmacokinetics with that of EFV-loaded micelles and pure EFV NPs. Materials & methods: EFV-loaded PCL ... -
In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems
Semete, Boitumelo; Booysen, Laetitia; Lemmer, Yolandy; Kalombo, Lonji; Katata, Lebogang; Verschoor, Jan (Elsevier Inc., 2010-10)The remarkable physicochemical properties of particles in the nanometer range have been proven to address many challenges in the field of science. However, the possible toxic effects of these particles have raised some ... -
Nanoencapsulation of water-soluble drug, lamivudine, using a double emulsion spray-drying technique for improving HIV treatment
Tshweu, Lesego; Katata, Lebogang; Kalombo, Lonji; Swai, Hulda (Springer Nature Switzerland AG., 2013-10-22)Current treatments available for human immunodeficiency virus, namely antiretrovirals, do not completely eradicate the virus from the body, leading to life-time commitment. Many antiretrovirals suffer drawbacks from ...